Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
King Pharmaceuticals
 | |
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceutical company, health care |
| Founded | 1994 |
| Headquarters | Bristol, Tennessee, U.S. |
Key people | Brian Markison (CEO) Joseph Squicciarino (CFO) Eric J. Bruce (CTO) |
| Products | Pharmaceuticals |
| Revenue | $1.7 billion USD (2009)[1] |
| $236 million USD (2009)[1] | |
| $92 million USD (2009)[1] | |
Number of employees | 3,381 |
| Parent | Pfizer |
| Website | kingpharm |
King Pharmaceuticals, Inc. is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company.[1][2] On October 12, 2010, King was acquired by Pfizer for $14.25 per share.[3] King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.
King Pharmaceuticals, Inc. was incorporated in the State of Tennessee in 1993. According to the King Pharmaceutcals, Inc. Form 10-K for the year ended December 31, 2007 filed with the U.S. Securities and Exchange Commission, the wholly owned subsidiaries of King Pharmaceuticals, Inc. are Monarch Pharmaceuticals, Inc.; King Pharmaceuticals Research and Development, Inc.; Meridian Medical Technologies, Inc.; Parkedale Pharmaceuticals, Inc.; King Pharmaceuticals Canada Inc.; and Monarch Pharmaceuticals Ireland Limited.[4]
- ^ a b c d "Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.
- ^ "Pharmaceutical Executive - 2006 Top 50 Pharmaceutical Companies" (PDF). Archived from the original (PDF) on 2011-07-11. Retrieved 2007-12-20.
- ^ "Pfizer to Buy King Pharmaceuticals for $3.6 Billion". The New York Times. October 12, 2010.
- ^ "King Pharmaceuticals, Inc. Form 10-K, Annual report for the fiscal year ended December 31, 2007". SEC Edgar.
Previous Page Next Page
